...Wei Du; Chang Xu; Zhiyuan Cheng; Zhenyu Sun; Shicheng Guo; Qiang Li; Yuanlin Song; Bo Shen; Yang Bao; Junjie Wu Introduction: With high incidence and mortality rates, lung cancer is now one of the most common cancers in the world. The 5-year survival rate of lung cancer patients is very low...

... to PPC in lung cancer patients with chronic obstructive pulmonary disease (COPD). Methods: This single-center retrospective cohort study included 40 patients with lung cancer complicated by COPD who underwent a preoperative cardiopulmonary exercise test between January 2017 and March 2024. Patients were...

...Wenrong Lin; XiaoJun Cai; YiJin Lin; Weikun Su; Guibin Weng; Lin Chen; Jianming Ding; Yibin Cai Introduction: Studies have shown that immune-related genes play a crucial role in tumor development and treatment. However, the specific roles and potential value of these genes in lung cancer patients...

...Bin Xie; Wenyan Dong; Fengping He; Feng Peng; Honghua Zhang; Wei Wang Introduction: The study explored the effects of SHOX2 and RASSF1A DNA methylation in lung cancer (LC). Method: Bronchoalveolar lavage fluid (BALF) samples as well as LC and normal adjacent tissues were collected from 72 LC...

...Udit Nindra; Victoria Bray; Deme Karikios; Mohsen Shafiei; Shalini Subramaniam; Pei Ding; Steven Kao; Abhijit Pal Introduction: Local Australian guidelines for the optimal management of stage III unresectable non-small cell lung cancer (NSCLC) are lacking. The American Society of Clinical Oncology...

... investigated the prognostic significance of inflammatory and nutritional markers in patients with advanced non-small cell lung cancer (NSCLC) receiving Nivo-Ipi. Methods: Our study retrospectively analyzed 101 patients with advanced NSCLC who received Nivo-Ipi at a single institution. Inflammatory...

... Nakajima; Kazuhisa Takahashi Introduction: Cisplatin-based chemotherapy was established in the 1980s, and it has been improved by the development of a short hydration protocol in lung cancer therapy. However, cisplatin-based chemotherapy is still associated with renal toxicity. Because 5-aminolevulinic...

...Yuki Sakai; Qiliang Zhou; Yoshifumi Matsumoto; Takuro Saiki; Masato Moriyama; Akira Toyama; Yasuo Saijo Introduction: Because of the increasing age of the general population, there is an increasing number of older patients with lung cancer. Cancer chemotherapy often causes severe hematological...

... was conducted to investigate whether polymorphisms in glycolysis-related genes are associated with clinical outcomes of patients with advanced-stage non-small cell lung cancer (NSCLC) undergoing chemotherapy. Methods: A total of 377 patients with NSCLC were enrolled. Sixty-five single-nucleotide polymorphisms...

... to in the content or advertisements. Immune exhaustion OX40 OX40 ligand Lung cancer Immunotherapy Serum OX40 and OX40L levels may reflect the immune-exhausted state of patients with advanced lung adenocarcinoma and predict prognosis. The authors would like to thank Koji Nishikawa, who...

... assessed sCD27 levels in patients with advanced lung cancer and determined their correlation with survival and clinicopathologic parameters. Methods: Serum samples were collected from patients with advanced lung cancer, and sCD27 was quantified via enzyme-linked immunosorbent assay. The association between...

...Martin Faehling; Marcel Kopp; Birgit Schwenk; Sabine Fallscheer; Sebastian Kramberg; Robert Eckert Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized...

... and clinico-pathological characteristics of lung cancer in patients younger than 40 years. Materials and Methods: This was a prospective study performed within the Groupe Français de Pneumo-Cancérologie. Consecutive patients diagnosed with lung cancer before the age of 40 years were eligible. Data...

... if a high dose of radiation could be delivered safely and provide a clinical benefit. Methods: Consecutive patients with stage IIIA or IIIB non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy followed by surgery were reviewed with IRB approval. Results: A total of 48 patients were...

...; Jorge Otero; Oscar Arrieta Objective: This study describes the real-world characteristics, treatment sequencing, and outcomes among Hispanic patients with locally advanced/metastatic ALK-positive non-small-cell lung cancer (NSCLC) treated with crizotinib. Methods: A retrospective patient review...

...Raya Saba; Oleksandr Halytskyy; Nasir Saleem; Ira A. Oliff Lung cancer is currently the leading cause of cancer-related mortality among men and women in the United States, and optimal screening methods are still lacking. The field effect is a well-supported phenomenon wherein a noxious stimulus...

...Tobias R. Overbeck; Johanna Arnemann; Regina Waldmann-Beushausen; Lorenz Trümper; Friedrich A. Schöndube; Kirsten Reuter-Jessen; Bernhard C. Danner Background: ATP-binding cassette transport protein A3 (ABCA3) is expressed in non-small cell lung cancer (NSCLC). We hypothesize that high-level ABCA3...

... is a positive or negative immunomodulator, but its effects on the regulation of T cells could inhibit the antitumor activity elicited by nivolumab (NIVO). We aimed to assess whether the occurrence of hyperprolactinemia in metastatic non-small cell lung cancer (mNSCLC) patients treated with NIVO is associated...

...Francesca Sanguedolce; Domenico Loizzi; Francesco Sollitto; Maurizio Di Bisceglie; Giuseppe Lucarelli; Giuseppe Carrieri; Pantaleo Bufo; Luigi Cormio Lung cancer is the tumor with the highest incidence in males worldwide and the most common cause of death from cancer overall; its high mortality...

...Katalin Fábián; Márton Gyulai; József Furák; Péter Várallyay; Márta Jäckel; Krisztina Bogos; Balázs Döme; Judit Pápay; József Tímár; Zoltán Szállási; Judit Moldvay Background: Brain metastasis of lung cancer adversely affects overall survival (OS) and quality of life, while peritumoral brain edema...